Breast CancerPhase 3NCT00382070
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
A Phase 3 study testing Letrozole in people with Breast Cancer, run by NSABP Foundation Inc at 806 sites in 3 countries.
Trial summary
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether letrozole is more effective than a placebo in treating patients with hormone receptor-positive breast cancer. Read more about this study
- Who is it for?
- Ages 18 to 120 years, women only
- Conditions the study is for
- Breast Cancer
- What is being tested?
- Letrozole
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 3,966 participants
- Where
- 806 sitesin 3 countries
- Study dates
- Aug 2006to Apr 2025
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 120 years
- Women only
- No healthy volunteers
- Adult, Older adult
Eligibility Criteria
- Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (0 = fully active, able to carry on all pre-disease performance without restriction; 1 = restricted in physically strenuous activity but ambulatory).
- Patients must be postmenopausal at the time of randomization. (Note: Premenopausal or perimenopausal women requiring therapy with luteinizing hormone-releasing hormone [LHRH] analogs to suppress ovarian function are not eligible.) For study purposes, postmenopausal is defined as: age 56 or older with no spontaneous menses for at least 12 months prior to study entry, or age 55 or younger with no spontaneous menses for at least 12 months prior to study entry (e.g., spontaneous or secondary to hysterectomy) AND with a documented estradiol level in the postmenopausal range according to local institutional/laboratory standards, or a prior documented bilateral oophorectomy.
- The patient must have remained disease-free from the time of initial breast cancer diagnosis until the time of randomization.
- The patient must have had histologically-confirmed invasive carcinoma of the breast by diagnostic core needle biopsy or by final pathologic evaluation of the surgical specimen.
- Patients who received neoadjuvant chemotherapy must have been clinical Stage I, II, or IIIA. For patients who received adjuvant chemotherapy, the primary tumor must have been T1-3 on pathologic evaluation and ipsilateral nodes must have been pN0, pN1 (pN1mi, pN1a, pN1b, pN1c), pN2a, pN3a, or pN3b.
- The primary tumor must have been estrogen receptor (ER)-positive and/or progesterone receptor (PgR)-positive. (Patients who had a tumor that was considered to be borderline for hormone receptor positivity and who were treated with tamoxifen and/or an aromatases inhibitor (AI) are eligible for this study.)
- Patients must have undergone either a lumpectomy with axillary nodal staging followed by breast radiotherapy or a total mastectomy with axillary nodal staging. (Acceptable axillary nodal staging procedures include sentinel node biopsy alone, if sentinel nodes were negative on hematoxylin and eosin (H\&E) staining.)
- The duration of the patient's hormonal therapy following breast cancer diagnosis must have been 57-63 months from the first dose regardless of the number of missed doses. Hormonal therapy must have consisted of an AI or a combination of up to 3 years of tamoxifen followed by an AI. Tamoxifen may not have been given during years 4 and 5 of the 5 years of adjuvant hormonal therapy. (Note: Patients must discontinue their adjuvant AI therapy at the time of randomization.)
- Optional Letrozole Registration Program for patients who have not yet completed 5 years of hormonal therapy. (Note: As of September 5, 2008, the optional NSABP B-42 Registration Program closed to patient enrollment. Accrual and data collection for the NSABP B-42 randomized treatment trial continues as planned.) In order to have a predominantly letrozole-treated population for B-42 study entry, patients who have had a minimum of 2 years of hormonal therapy and who are currently on tamoxifen (for up to 3 years) or an AI may be offered letrozole at no cost until they complete 5 total years of initial adjuvant hormonal therapy.
- B-42 randomization must be within 6 months following completion of 5 years (57-63 months) of initial adjuvant hormonal therapy.
- At the time of randomization, the patient must have had the following: history and physical exam within 3 months demonstrating no findings suggestive of recurrent breast cancer; bilateral mammogram within 1 year (unilateral if patient had a mastectomy); mammogram not required if patient had a prophylactic contralateral mastectomy; bone mineral density (BMD) testing within 1 year; and fasting lipid profile (total cholesterol, LDL-C, HDL-C, and triglycerides) with a total cholesterol value less than or equal to grade 1 (according to CTCAE v3.0), with or without cholesterol-lowering therapy.
- within 1 year if the patient has a history of hypercholesterolemia controlled with cholesterol-lowering therapy and/or therapeutic lifestyle changes or if the patient has a history of one or more of the following risk factors for future cardiovascular events: diabetes, hypertension, obesity, tobacco use, hypertriglyceridemia, documented coronary artery disease, or family history of premature coronary heart disease.
- within 2 years for all other patients.
Ineligibility Criteria
- Patients with one or more of the following conditions will be ineligible for this study:
- History of non-traumatic osteoporotic fracture of wrist, hip, or spine.
- Diagnosis of bilateral breast cancer including ductal carcinoma in situ (DCIS)[(synchronous or metachronous].
- Other malignancies unless the patient is considered to be disease-free for 5 or more years prior to randomization, and is deemed by their physician to be at low risk for recurrence. Patients with the following cancers are eligible if diagnosed and treated within the past 5 years: carcinoma in situ of the cervix, colon carcinoma in situ, melanoma in situ, and basal cell and squamous cell carcinoma of the skin.
- Sex hormonal therapy, e.g., estrogen- or progesterone-replacement therapy or oral contraceptives. These patients are eligible only if this therapy is discontinued prior to randomization.
- Therapy with any hormonal agent such as raloxifene for management of osteoporosis. Patients are eligible only if these medications are discontinued prior to study entry.
- Administration of any investigational agent within 30 days before study entry.
Trial locations and contacts
806 sites in 3 countries.
329 sites in 3 countries
United States300 sites
Kapiolani Medical Center at Pali Momi
‘Aiea, Hawaii, 96701
Hickman Cancer Center at Bixby Medical Center
Adrian, Michigan, 49221
McDowell Cancer Center at Akron General Medical Center
Akron, Ohio, 44307
Summa Center for Cancer Care at Akron City Hospital
Akron, Ohio, 44309-2090
Phoebe Cancer Center at Phoebe Putney Memorial Hospital
Albany, Georgia, 31701
New York Oncology Hematology, PC at Albany Regional Cancer Care
Albany, New York, 12206
New York Oncology Hematology, PC at Albany Medical Center
Albany, New York, 12208
Lovelace Medical Center - Downtown
Albuquerque, New Mexico, 87102
Hematology Oncology Associates, PC
Albuquerque, New Mexico, 87106
New Mexico Cancer Center
Albuquerque, New Mexico, 87109
University of New Mexico Cancer Center
Albuquerque, New Mexico, 87131-5636
Sacred Heart Hospital
Allentown, Pennsylvania, 18102
Morgan Cancer Center at Lehigh Valley Hospital - Cedar Crest
Allentown, Pennsylvania, 18105
Saint Anthony's Hospital at Saint Anthony's Health Center
Alton, Illinois, 62002
American Fork Hospital
American Fork, Utah, 84003
McFarland Clinic, PC
Ames, Iowa, 50010
Amsterdam Community Cancer Program
Amsterdam, New York, 12010
Providence Cancer Center
Anchorage, Alaska, 99508
AnMed Cancer Center
Anderson, South Carolina, 29621
Saint Joseph Mercy Cancer Center
Ann Arbor, Michigan, 48106-0995
CCOP - Michigan Cancer Research Consortium
Ann Arbor, Michigan, 48106
Regional Medical Center
Anniston, Alabama, 36202
Hospital District Sixth of Harper County
Anthony, Kansas, 67003
Randolph Hospital
Asheboro, North Carolina, 27203-5400
Hope A Women's Cancer Center
Asheville, North Carolina, 28801
Mission Hospitals - Memorial Campus
Asheville, North Carolina, 28801
Cancer Resource Center at King's Daughters Medical Center
Ashland, Kentucky, 41101-0151
Cancer Care at Our Lady of Bellefonte Hospital
Ashland, Kentucky, 41101
Northeast Georgia Cancer Care, LLC - Medical Oncology
Athens, Georgia, 30607
Georgia Cancer Center for Excellence at Grady Memorial Hospital
Atlanta, Georgia, 30303
Emory Crawford Long Hospital
Atlanta, Georgia, 30308
Piedmont Hospital
Atlanta, Georgia, 30309
Winship Cancer Institute of Emory University
Atlanta, Georgia, 30322
Northside Hospital Cancer Center
Atlanta, Georgia, 30342-1611
Saint Joseph's Hospital of Atlanta
Atlanta, Georgia, 30342-1701
CCOP - Atlanta Regional
Atlanta, Georgia, 30342
Sturdy Memorial Hospital
Attleboro, Massachusetts, 02703
Auburn Regional Center for Cancer Care
Auburn, Washington, 98002
Augusta Oncology Associates - Walton Way
Augusta, Georgia, 30901
MBCCOP - Medical College of Georgia Cancer Center
Augusta, Georgia, 30912
Aurora Presbyterian Hospital
Aurora, Colorado, 80012
University of Colorado Cancer Center at UC Health Sciences Center
Aurora, Colorado, 80045
WellStar Cobb Hospital
Austell, Georgia, 30106
Southwest Regional Cancer Center - Central
Austin, Texas, 78705
Texas Oncology, PA at Texas Oncology Cancer Center - Central
Austin, Texas, 78731
Texas Oncology, PA - Austin Northwest
Austin, Texas, 78759
Texas Oncology, PA - Austin North
Austin, Texas, 78759
Mercy Medical Center
Baltimore, Maryland, 21202
Greater Baltimore Medical Center Cancer Center
Baltimore, Maryland, 21204
St. Agnes Hospital Cancer Center
Baltimore, Maryland, 21229
Harry & Jeanette Weinberg Cancer Institute at Franklin Square Hospital Center
Baltimore, Maryland, 21237
CancerCare of Maine at Eastern Maine Medical Center
Bangor, Maine, 04401
Barberton Citizens Hospital
Barberton, Ohio, 44203
Pennington Cancer Center at Baton Rouge General
Baton Rouge, Louisiana, 70806
Mary Bird Perkins Cancer Center - Baton Rouge
Baton Rouge, Louisiana, 70809
Ochsner Health Center - Bluebonnet
Baton Rouge, Louisiana, 70809
Battle Creek Health System Cancer Care Center
Battle Creek, Michigan, 49017
Bay Regional Medical Center
Bay City, Michigan, 48708
Cleveland Clinic Beachwood Family Health and Surgery Center
Beachwood, Ohio, 44122
St. Francis Hospital and Health Centers - Beech Grove Campus
Beech Grove, Indiana, 46107
Mary Rutan Hospital
Bellefontaine, Ohio, 43311
Overlake Cancer Center at Overlake Hospital Medical Center
Bellevue, Washington, 98004
St. Joseph Cancer Center
Bellingham, Washington, 98225
MeritCare Bemidji
Bemidji, Minnesota, 56601
St. Charles Medical Center - Bend
Bend, Oregon, 97701
Alta Bates Summit Comprehensive Cancer Center
Berkeley, California, 94704
Mountainview Medical
Berlin Corners, Vermont, 05602
Suburban Hospital
Bethesda, Maryland, 20814
St. Luke's Cancer Network at St. Luke's Hospital
Bethlehem, Pennsylvania, 18015
Hematology Oncology Associates of the Quad Cities
Bettendorf, Iowa, 52722
Study site
Bettendorf, Iowa, 52722
Mecosta County Medical Center
Big Rapids, Michigan, 49307
CCOP - Montana Cancer Consortium
Billings, Montana, 59101
Hematology-Oncology Centers of the Northern Rockies - Billings
Billings, Montana, 59101
Northern Rockies Radiation Oncology Center
Billings, Montana, 59101
St. Vincent Healthcare Cancer Care Services
Billings, Montana, 59101
Billings Clinic - Downtown
Billings, Montana, 59107-7000
Bismarck Cancer Center
Bismarck, North Dakota, 58501
Medcenter One Hospital Cancer Care Center
Bismarck, North Dakota, 58501
Mid Dakota Clinic, PC
Bismarck, North Dakota, 58501
St. Alexius Medical Center Cancer Center
Bismarck, North Dakota, 58502
St. Joseph Medical Center
Bloomington, Illinois, 61701
Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - West
Boca Raton, Florida, 33428
Eugene M. and Christine E. Lynn Cancer Institute at Boca Raton Community Hospital - Main Campus
Boca Raton, Florida, 33486
Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center
Boise, Idaho, 83706
Mountain States Tumor Institute at St. Luke's Regional Medical Center
Boise, Idaho, 83712
Tufts-NEMC Cancer Center
Boston, Massachusetts, 02111
Boston University Cancer Research Center
Boston, Massachusetts, 02118
Boulder Community Hospital
Boulder, Colorado, 80301-9019
Wood County Oncology Center
Bowling Green, Ohio, 43402
Bozeman Deaconess Cancer Center
Bozeman, Montana, 59715
Olympic Hematology and Oncology
Bremerton, Washington, 98310
Ocean Medical Center at Meridian Health
Brick, New Jersey, 08724
Bridgeport Hospital
Bridgeport, Connecticut, 06610
Bristol Hospital
Bristol, Connecticut, 06011-0977
Coney Island Hospital
Brooklyn, New York, 11235
St. Joseph Regional Cancer Center
Bryan, Texas, 77802
Bryn Mawr Hospital
Bryn Mawr, Pennsylvania, 19010
Roswell Park Cancer Institute
Buffalo, New York, 14263-0001
Providence Saint Joseph Medical Center - Burbank
Burbank, California, 91505
Peninsula Medical Center
Burlingame, California, 94010
Lahey Clinic Medical Center - Burlington
Burlington, Massachusetts, 01805
Alamance Cancer Center at Alamance Regional Medical Center
Burlington, North Carolina, 27216
Fletcher Allen Health Care - University Health Center Campus
Burlington, Vermont, 05401
Fairview Ridges Hospital
Burnsville, Minnesota, 55337
St. James Healthcare Cancer Care
Butte, Montana, 59701
Graham Hospital
Canton, Illinois, 61520
Mercy Cancer Center at Mercy Medical Center
Canton, Ohio, 44708
Aultman Cancer Center at Aultman Hospital
Canton, Ohio, 44710-1799
Saint Francis Medical Center
Cape Girardeau, Missouri, 63703
Waverly Hematology Oncology
Cary, North Carolina, 27511
East Bay Radiation Oncology Center
Castro Valley, California, 94546
Eden Medical Center
Castro Valley, California, 94546
Valley Medical Oncology Consultants - Castro Valley
Castro Valley, California, 94546
Sandra L. Maxwell Cancer Center
Cedar City, Utah, 84720
Texas Oncology, PA - Cedar Park
Cedar Park, Texas, 78613
Iowa Blood and Cancer Care
Cedar Rapids, Iowa, 52402
St. Luke's Hospital
Cedar Rapids, Iowa, 52402
Cedar Rapids Oncology Associates
Cedar Rapids, Iowa, 52403
Mercy Regional Cancer Center at Mercy Medical Center
Cedar Rapids, Iowa, 52403
Providence Centralia Hospital
Centralia, Washington, 98531-9027
Cancer Center of Kansas, PA - Chanute
Chanute, Kansas, 66720
Roper St. Francis Cancer Center at Roper Hospital
Charleston, South Carolina, 29401
Hollings Cancer Center at Medical University of South Carolina
Charleston, South Carolina, 29425
West Virginia University Health Sciences Center - Charleston
Charleston, West Virginia, 25304
Blumenthal Cancer Center at Carolinas Medical Center
Charlotte, North Carolina, 28232-2861
Presbyterian Cancer Center at Presbyterian Hospital
Charlotte, North Carolina, 28233-3549
Saint Luke's Hospital
Chesterfield, Missouri, 63017
Rush University Medical Center
Chicago, Illinois, 60612
Resurrection Medical Center
Chicago, Illinois, 60631
University of Chicago Cancer Research Center
Chicago, Illinois, 60637-1470
Louis A. Weiss Memorial Hospital
Chicago, Illinois, 60640
Creticos Cancer Center at Advocate Illinois Masonic Medical Center
Chicago, Illinois, 60657
Adena Regional Medical Center
Chillicothe, Ohio, 45601
Marshfield Clinic - Chippewa Center
Chippewa Falls, Wisconsin, 54729
Christ Hospital Cancer Center
Cincinnati, Ohio, 45219
Oncology Hematology Care, Incorporated - Blue Ash
Cincinnati, Ohio, 45242
United Hospital Center
Clarksburg, West Virginia, 26301
Morton Plant Hospital
Clearwater, Florida, 33756
Case Comprehensive Cancer Center
Cleveland, Ohio, 44106-5065
MetroHealth Cancer Care Center at MetroHealth Medical Center
Cleveland, Ohio, 44109
Cleveland Clinic Cancer Center at Fairview Hospital
Cleveland, Ohio, 44111
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio, 44195
North Coast Cancer Care - Clyde
Clyde, Ohio, 43410
Kootenai Cancer Center - Coeur d'Alene
Coeur d'Alene, Idaho, 83814
Memorial Hospital Cancer Center - Colorado Springs
Colorado Springs, Colorado, 80909
Penrose Cancer Center at Penrose Hospital
Colorado Springs, Colorado, 80933
Ellis Fischel Cancer Center at University of Missouri - Columbia
Columbia, Missouri, 65203
John B. Amos Cancer Center
Columbus, Georgia, 31904
Arthur G. James Cancer Hospital and Solove Research Institute at Ohio State University Medical Center
Columbus, Ohio, 43210-1240
Riverside Methodist Hospital Cancer Care
Columbus, Ohio, 43214-3998
CCOP - Columbus
Columbus, Ohio, 43215
Grant Medical Center Cancer Care
Columbus, Ohio, 43215
Mount Carmel Health - West Hospital
Columbus, Ohio, 43222
Doctors Hospital at Ohio Health
Columbus, Ohio, 43228
Cancer Care Center at John Muir Health - Concord Campus
Concord, California, 94524-4110
Commonwealth Hematology-Oncology, PC - Concord
Concord, Massachusetts, 01742
New Hampshire Oncology - Hematology, PA at Payson Center for Cancer Care
Concord, New Hampshire, 03301
Batte Cancer Center at Northeast Medical Center
Concord, North Carolina, 28025
Mercy and Unity Cancer Center at Mercy Hospital
Coon Rapids, Minnesota, 55433
Bay Area Hospital
Coos Bay, Oregon, 97420
Heartland Oncology and Hematology
Council Bluffs, Iowa, 51503
Medical City Dallas Hospital
Dallas, Texas, 75230
Presbyterian Hospital of Dallas
Dallas, Texas, 75231
Praxair Cancer Center at Danbury Hospital
Danbury, Connecticut, 06810
Geisinger Cancer Institute at Geisinger Health
Danville, Pennsylvania, 17822-0001
Mercy Fitzgerald Hospital
Darby, Pennsylvania, 19023
Genesis Regional Cancer Center at Genesis Medical Center
Davenport, Iowa, 52803
Genesis Medical Center - West Campus
Davenport, Iowa, 52804
Grandview Hospital
Dayton, Ohio, 45405
Good Samaritan Hospital
Dayton, Ohio, 45406
David L. Rike Cancer Center at Miami Valley Hospital
Dayton, Ohio, 45409
Samaritan North Cancer Care Center
Dayton, Ohio, 45415
CCOP - Dayton
Dayton, Ohio, 45420
Herbert D. Kerman Regional Oncology Center - Daytona Beach
Daytona Beach, Florida, 32114
Oakwood Cancer Center at Oakwood Hospital and Medical Center
Dearborn, Michigan, 48123-2500
Charles B. Eberhart Cancer Center at DeKalb Medical Center
Decatur, Georgia, 30033
Decatur Memorial Hospital Cancer Care Institute
Decatur, Illinois, 62526
North Broward Medical Center
Deerfield Beach, Florida, 33064-3596
Grady Memorial Hospital
Delaware, Ohio, 43015
Denver Health Medical Center
Denver, Colorado, 80204
St. Anthony Central Hospital
Denver, Colorado, 80204
Porter Adventist Hospital
Denver, Colorado, 80210
Presbyterian - St. Luke's Medical Center
Denver, Colorado, 80218
St. Joseph Hospital
Denver, Colorado, 80218
Rose Medical Center
Denver, Colorado, 80220
Veterans Affairs Medical Center - Denver
Denver, Colorado, 80220
CCOP - Colorado Cancer Research Program
Denver, Colorado, 80224-2522
Mercy Capitol Hospital
Des Moines, Iowa, 50307
CCOP - Iowa Oncology Research Association
Des Moines, Iowa, 50309
John Stoddard Cancer Center at Iowa Methodist Medical Center
Des Moines, Iowa, 50309
Medical Oncology and Hematology Associates at Mercy Cancer Center
Des Moines, Iowa, 50314
Mercy Cancer Center at Mercy Medical Center - Des Moines
Des Moines, Iowa, 50314
John Stoddard Cancer Center at Iowa Lutheran Hospital
Des Moines, Iowa, 50316
Barbara Ann Karmanos Cancer Institute
Detroit, Michigan, 48201-1379
Josephine Ford Cancer Center at Henry Ford Hospital
Detroit, Michigan, 48202
Cancer Center of Kansas, PA - Dodge City
Dodge City, Kansas, 67801
Commonwealth Hematology Oncology PC - Dorchester
Dorchester, Massachusetts, 02124
Seacoast Cancer Center at Wentworth - Douglass Hospital
Dover, New Hampshire, 03820
City of Hope Comprehensive Cancer Center
Duarte, California, 91010-3000
Oncology Hematology Associates of Northern Pennsylvania, PC at Hahne Regional Cancer Center
DuBois, Pennsylvania, 15801
Duluth Clinic Cancer Center - Duluth
Duluth, Minnesota, 55805-1983
CCOP - Duluth
Duluth, Minnesota, 55805
Miller - Dwan Medical Center
Duluth, Minnesota, 55805
St. Luke's Hospital Cancer Care Center
Duluth, Minnesota, 55805
Dale and Frances Hughes Cancer Center at Pocono Medical Center
East Stroudsburg, Pennsylvania, 18301
CCOP - Hematology-Oncology Associates of Central New York
East Syracuse, New York, 13057
Shore Regional Cancer Center at Memorial Hospital - Easton
Easton, Maryland, 21601
Marshfield Clinic Cancer Care at Regional Cancer Center
Eau Claire, Wisconsin, 54701
Luther Midlelfort Hospital
Eau Claire, Wisconsin, 54702
Midelfort Clinic - Luther
Eau Claire, Wisconsin, 54703-1510
Fairview Southdale Hospital
Edina, Minnesota, 55435
Shaw Regional Cancer Center
Edwards, Colorado, 81632
Cancer Center of Kansas, PA - El Dorado
El Dorado, Kansas, 67042
Sherman Hospital
Elgin, Illinois, 60120
Alexian Brothers Radiation Oncology
Elk Grove Village, Illinois, 60007
Elkhart General Hospital
Elkhart, Indiana, 46515
Vince Lombardi Cancer Center at Aurora Lakeland Medical Center - Elkhorn
Elkhorn, Wisconsin, 53121
Union Hospital Cancer Program at Union Hospital
Elkton, Maryland, 21921
Elmhurst Memorial Hospital
Elmhurst, Illinois, 60126
Hematology Oncology Center
Elyria, Ohio, 44035
Swedish Medical Center
Englewood, Colorado, 80110
Dizzy Gillespie Cancer Institute at Englewood Hospital and Medical Center
Englewood, New Jersey, 07631
Green Bay Oncology, Limited - Escanaba
Escanaba, Michigan, 49431
Eureka Community Hospital
Eureka, Illinois, 61530
Evanston Hospital
Evanston, Illinois, 60201-1781
Center for Cancer Care at Exeter Hospital
Exeter, New Hampshire, 03833
Fairbanks Cancer Treatment Center at Fairbanks Memorial Hospital
Fairbanks, Alaska, 99701
North Bay Cancer Center
Fairfield, California, 94533
Hudner Oncology Center at Saint Anne's Hospital - Fall River
Fall River, Massachusetts, 02721
Dakota Cancer Institute at Dakota Clinic - South University
Fargo, North Dakota, 58103
CCOP - MeritCare Hospital
Fargo, North Dakota, 58122
MeritCare Broadway
Fargo, North Dakota, 58122
Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
Farmington, Connecticut, 06360-2875
St. Francis Hospital
Federal Way, Washington, 98003
Blanchard Valley Medical Associates
Findlay, Ohio, 45840
Simonds-Sinon Regional Cancer Center at HealthAlliance Hospital - Burbank Campus
Fitchburg, Massachusetts, 01420
Hunterdon Regional Cancer Center at Hunterdon Medical Center
Flemington, New Jersey, 08822
Genesys Hurley Cancer Institute
Flint, Michigan, 48503
Hurley Medical Center
Flint, Michigan, 48503
Great Lakes Cancer Institute at McLaren Regional Medical Center
Flint, Michigan, 48532
McLeod Regional Medical Center
Florence, South Carolina, 29501
Poudre Valley Hospital
Fort Collins, Colorado, 80524
Front Range Cancer Specialists
Fort Collins, Colorado, 80528
Michael and Dianne Bienes Comprehensive Cancer Center at Holy Cross Hospital
Fort Lauderdale, Florida, 33308
Cancer Center of Kansas - Fort Scott
Fort Scott, Kansas, 66701
Middletown Regional Hospital
Franklin, Ohio, 45005-1066
Frederick Memorial Hospital Regional Cancer Therapy Center
Frederick, Maryland, 21701
Fredericksburg Oncology, Incorporated
Fredericksburg, Virginia, 22401
CentraState Medical Center
Freehold, New Jersey, 07728
Kaiser Permanente - Fremont
Fremont, California, 94538
Valley Medical Oncology
Fremont, California, 94538
Cancer Care Associates
Fresno, California, 93720
Mercy and Unity Cancer Center at Unity Hospital
Fridley, Minnesota, 55432
Virginia K. Crosson Cancer Center at St. Jude Medical Center
Fullerton, California, 92835
University of Florida Shands Cancer Center
Gainesville, Florida, 32610-0232
Northeast Georgia Medical Center
Gainesville, Georgia, 30501
Galesburg Clinic, PC
Galesburg, Illinois, 61401
Galesburg Cottage Hospital
Galesburg, Illinois, 61401
CaroMont Cancer Center at Gaston Memorial Hospital
Gastonia, North Carolina, 28053
Georgetown Memorial Hospital
Georgetown, South Carolina, 29440
Glendale Memorial Hospital Comprehensive Cancer Center
Glendale, California, 91204
Oncology Alliance, SC - Milwaukee - East
Glendale, Wisconsin, 53212-1038
Adirondack Cancer Care - Glens Falls
Glens Falls, New York, 12801
Charles R. Wood Cancer Center at Glens Falls Hospital
Glens Falls, New York, 12801
Addison Gilbert Hospital
Gloucester, Massachusetts, 01930
Wayne Memorial Hospital, Incorporated
Goldsboro, North Carolina, 27534
Center for Cancer Care at Goshen General Hospital
Goshen, Indiana, 46526
Altru Cancer Center at Altru Hospital
Grand Forks, North Dakota, 58201
Saint Francis Cancer Treatment Center at Saint Francis Memorial Health Center
Grand Island, Nebraska, 68803
St. Mary's Regional Cancer Center at St. Mary's Hospital and Medical Center
Grand Junction, Colorado, 81502
Butterworth Hospital at Spectrum Health
Grand Rapids, Michigan, 49503
CCOP - Grand Rapids
Grand Rapids, Michigan, 49503
Lacks Cancer Center at Saint Mary's Health Care
Grand Rapids, Michigan, 49503
Three Rivers Community Hospital
Grants Pass, Oregon, 97527
Big Sky Oncology
Great Falls, Montana, 59405-5309
Sletten Cancer Institute at Benefis Healthcare
Great Falls, Montana, 59405
Study site
Great Falls, Montana, 59405
North Colorado Medical Center
Greeley, Colorado, 80631
Green Bay Oncology, Limited at St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54301-3526
Green Bay Oncology, Limited at St. Mary's Hospital
Green Bay, Wisconsin, 54303
St. Mary's Hospital Medical Center - Green Bay
Green Bay, Wisconsin, 54303
St. Vincent Hospital Regional Cancer Center
Green Bay, Wisconsin, 54307-3508
Vince Lombardi Cancer Clinic - Green Bay at Aurora BayCare Medical Center
Green Bay, Wisconsin, 54311
Marin Cancer Institute at Marin General Hospital
Greenbrae, California, 94904
Sutter Health - Western Division Cancer Research Group
Greenbrae, California, 94904
Moses Cone Regional Cancer Center at Wesley Long Community Hospital
Greensboro, North Carolina, 27403-1198
Leo W. Jenkins Cancer Center at ECU Medical School
Greenville, North Carolina, 27834
Wayne Hospital
Greenville, Ohio, 45331
CCOP - Greenville
Greenville, South Carolina, 29615
Legacy Mount Hood Medical Center
Gresham, Oregon, 97030
Van Elslander Cancer Center at St. John Hospital and Medical Center
Grosse Pointe Woods, Michigan, 48236
Cancer Institute of New Jersey at Hamilton
Hamilton, New Jersey, 08690
Helen and Harry Gray Cancer Center at Hartford Hospital
Hartford, Connecticut, 06102-5037
Saint Francis/Mount Sinai Regional Cancer Center at Saint Francis Hospital and Medical Center
Hartford, Connecticut, 06105
Hattiesburg Clinic, PA at Forrest General
Hattiesburg, Mississippi, 39401
Mason District Hospital
Havana, Illinois, 62644
Northern Montana Hospital
Havre, Montana, 59501
Kaiser Permanente Medical Center - Hayward
Hayward, California, 94545
Geisinger Hazleton Cancer Center
Hazleton, Pennsylvania, 18201
Canada18 sites
Northeastern Ontario Regional Cancer Centre
Greater Sudbury, Ontario, P3E 5J1
British Columbia Cancer Agency - Centre for the Southern Interior
Kelowna, British Columbia, V1Y 5L3
Cancer Centre of Southeastern Ontario at Kingston General Hospital
Kingston, Ontario, K7L 5P9
Carlo Fidani Peel Regional Cancer Centre at Credit Valley Hospital
Mississauga, Ontario, L5M 2N1
Hopital Notre-Dame du CHUM
Montreal, Quebec, H2L 4M1
CHUM - Hotel Dieu Hospital
Montreal, Quebec, H2W 1T8
CHUM - Hopital Saint-Luc
Montreal, Quebec, H2X 3J4
Royal Victoria Hospital - Montreal
Montreal, Quebec, H3A 1A1
Jewish General Hospital - Montreal
Montreal, Quebec, H3T 1E2
St. Mary's Hospital Center
Montreal, Quebec, H3T 1M5
Hopital du Saint-Sacrement - Quebec
Québec, Quebec, G1S 4L8
BCCA - Fraser Valley Cancer Centre
Surrey, British Columbia, V3V 1Z2
Cancer Care Program at Thunder Bay Regional Health Sciences
Thunder Bay, Ontario, P7B 6V4
Mount Sinai Hospital - Toronto
Toronto, Ontario, M5G 1X5
Princess Margaret Hospital
Toronto, Ontario, M5G 2M9
British Columbia Cancer Agency - Vancouver Cancer Centre
Vancouver, British Columbia, V5Z 4E6
British Columbia Cancer Agency - Vancouver Island Centre
Victoria, British Columbia, V8R 6V5
CancerCare Manitoba
Winnipeg, Manitoba, R3E 0V9
Ireland11 sites
Cork University Hospital
Cork
South Infirmary Victoria Hospital
Cork
Beaumont Hospital
Dublin, 0009
Adelaide and Meath Hospital, Dublin Incorporating the National Children's Hospital
Dublin, 24
St. Vincent's University Hospital
Dublin, 4
Mater Misericordiae University Hospital
Dublin, 7
St. James's Hospital
Dublin, 8
University College Hospital
Galway, GY.
Mid-Western Cancer Centre at Mid-Western Regional Hospital
Limerick, 0009
Sligo General Hospital
Sligo, Sligo
Waterford Regional Hospital
Waterford, 0009
About this study
Official title: A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether letrozole is more effective than a placebo in treating patients with hormone receptor-positive breast cancer.
PURPOSE: This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in treating postmenopausal women who have received hormone therapy for hormone receptor-positive breast cancer.
Read the detailed description
OBJECTIVES:
Primary
- Determine whether or not prolonged adjuvant hormonal therapy comprising letrozole vs placebo will improve disease-free survival of postmenopausal women with estrogen receptor-positive and/or progesterone receptor-positive breast cancer who have completed 5 years of hormonal therapy with 5 years of an aromatase inhibitor (AI) or 5 years of a combination of up to 3 years of tamoxifen citrate followed by an AI.
- Compare the disease-free survival of patients treated with these regimens.
Secondary
- Compare overall survival of patients treated with these regimens.
- Compare breast cancer-free interval of patients treated with these regimens.
- Compare distant recurrence in patients treated with these regimens.
- Compare the incidence of osteoporotic-related fractures (e.g., Colles', hip, and spine) in these patients treated with these regimens.
- Compare the incidence of arterial thrombotic events in patients treated with these regimens.
OUTLINE: This is a double-blind, multicenter, placebo-controlled, randomized study. Patients are stratified according to pathologic nodal status (negative vs positive), adjuvant tamoxifen citrate therapy (yes vs no), and lowest bone mineral density T score for lumbosacral spine, total hip, or femoral neck (> -2.0 vs ≤ -2.0 standard deviation). Patients are randomized to 1 of 2 treatment arms.
- Group I: Patients receive oral placebo once daily.
- Group II: Patients receive oral letrozole once daily.
In both arms, treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed annually.
PROJECTED ACCRUAL: A total of 3,840 patients will be accrued for this study.
- Conditions
- Breast Cancer
- Being tested
- Letrozole, Placebo
- Keywords
- stage I breast cancer, stage II breast cancer, stage IIIA breast cancer
- Medical subject headings
- Breast Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
LetrozoleDrug
Letrozole 2.5 mg taken orally once daily for 5 years
PlaceboOther
Placebo tablet taken orally once daily for 5 years
| Study group | Role | What they receive |
|---|---|---|
| Group 2 Letrozole | Experimental | Patients receive oral letrozole once daily for up to 5 years. Receives: Drug: Letrozole |
| Group 1 Placebo | Placebo comparator | Patients receive oral placebo once daily for up to 5 years. Receives: Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Disease-free Survival
Percentage of patients free from DFS events. DFS events include local, regional, or distant recurrence, second primary cancer or death from any cause prior to recurrence or second primary cancer.
Measured: 7 years.
Secondary outcomes (5)
Overall Survival
Percentage of patients alive
Measured: 7 years
Breast Cancer-free Interval
Cumulative incidence of breast-cancer-free interval events. BCFI events include local-regional recurrence, distant recurrence or contralateral breast cancer as a first event.
Measured: 7 years
Distant Recurrence
Cumulative incidence of distant recurrences.
Measured: 7 years
Osteoporotic-related Fractures
Cumulative incidence of osteoporotic-related fractures defined as Colles', hip or spinal fractures
Measured: 7 years
Arterial Thrombotic Events
Cumulative incidence of arterial thrombotic events, as defined by CTCAE version 4.0 (grade ≥1 stroke or transient ischaemic attack; grade ≥2 acute coronary syndrome or cerebrovascular ischaemia; grade ≥3 myocardial infarction, peripheral ischaemia, or visceral arterial ischaemia; and grade ≥4 selected thromboembolic events [cerebrovascular event, arterial insufficiency]).
Measured: 7 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Sep 2006 (estimated)
- Study startAug 2006
- Primary completion25 Aug 2016
- Study completionApr 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (3)Papers the sponsor has linked to this study.
- Other trials for Breast CancerStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Investigator
- Enrolment
- 3,966 participants (actual)
Sponsor and investigators
- Lead sponsor
- NSABP Foundation Inc
- Sponsor type
- Research network
- Collaborators
- National Cancer Institute (NCI), Novartis
- Responsible party
- Sponsor
- Investigators
- Norman Wolmark, MD, Principal investigator, NSABP Foundation Inc
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00382070
- Sponsor's protocol ID
- NSABP B-42
- Other IDs
- U10CA012027
- Status last verified
- Mar 2024
- First submitted
- 26 Sep 2006
- Last updated
- 22 Mar 2024
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
Publications
Mamounas EP, Lembersky B, Jeong JH, Cronin W, Harkins B, Geyer C, Wickerham DL, Paik S, Costantino J, Wolmark N. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer. 2006 Dec;7(5):416-21. doi: 10.3816/CBC.2006.n.061. No abstract available.
PubMed 17239269Rastogi P, Bandos H, Lucas PC, van 't Veer LJ, Wei JJ, Geyer CE Jr, Fehrenbacher L, Chia SKL, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Paik S, Swain SM, Menicucci AR, Audeh MW, Wolmark N, Mamounas EP. Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial. J Clin Oncol. 2024 Oct 20;42(30):3561-3569. doi: 10.1200/JCO.23.01995. Epub 2024 Jul 24.
PubMed 39047219Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer CE Jr, Rastogi P, Fehrenbacher L, Graham ML, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Seay TE, Wade JL 3rd, McCarron EC, Paik S, Swain SM, Wickerham DL, Wolmark N. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Jan;20(1):88-99. doi: 10.1016/S1470-2045(18)30621-1. Epub 2018 Nov 30.
PubMed 30509771
Study at a glance
From the registry record, last updated by the sponsor on 22 Mar 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
- ClinicalTrials.gov ID
- NCT00382070
- Acronym / sponsor ID
- NSABP B-42
- Conditions
- Breast Cancer
- Keywords
- stage I breast cancer, stage II breast cancer, stage IIIA breast cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 3,966 participants (actual)
- Lead sponsor
- NSABP Foundation IncResearch network
- Collaborators
- National Cancer Institute (NCI), Novartis
- Study start
- Aug 2006
- Primary completion
- 25 Aug 2016 (actual)
- Study completion
- Apr 2025 (estimated)
- First posted
- 28 Sep 2006 (estimated)
- Results
- Posted 20 May 2021
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes. It is not yet known whether letrozole is more effective than a placebo in treating patients with hormone receptor-positive breast cancer.
PURPOSE: This randomized phase III trial is studying letrozole to see how well it works compared with a placebo in treating postmenopausal women who have received hormone therapy for hormone receptor-positive breast cancer.
Detailed description
OBJECTIVES:
Primary
- Determine whether or not prolonged adjuvant hormonal therapy comprising letrozole vs placebo will improve disease-free survival of postmenopausal women with estrogen receptor-positive and/or progesterone receptor-positive breast cancer who have completed 5 years of hormonal therapy with 5 years of an aromatase inhibitor (AI) or 5 years of a combination of up to 3 years of tamoxifen citrate followed by an AI.
- Compare the disease-free survival of patients treated with these regimens.
Secondary
- Compare overall survival of patients treated with these regimens.
- Compare breast cancer-free interval of patients treated with these regimens.
- Compare distant recurrence in patients treated with these regimens.
- Compare the incidence of osteoporotic-related fractures (e.g., Colles', hip, and spine) in these patients treated with these regimens.
- Compare the incidence of arterial thrombotic events in patients treated with these regimens.
OUTLINE: This is a double-blind, multicenter, placebo-controlled, randomized study. Patients are stratified according to pathologic nodal status (negative vs positive), adjuvant tamoxifen citrate therapy (yes vs no), and lowest bone mineral density T score for lumbosacral spine, total hip, or femoral neck (> -2.0 vs ≤ -2.0 standard deviation). Patients are randomized to 1 of 2 treatment arms.
- Group I: Patients receive oral placebo once daily.
- Group II: Patients receive oral letrozole once daily.
In both arms, treatment continues for up to 5 years in the absence of disease progression or unacceptable toxicity.
After completion of study treatment, patients are followed annually.
PROJECTED ACCRUAL: A total of 3,840 patients will be accrued for this study.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, investigator)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Group 2 Letrozole | Experimental | Drug: LetrozolePatients receive oral letrozole once daily for up to 5 years. |
| Group 1 Placebo | Placebo comparator | Other: PlaceboPatients receive oral placebo once daily for up to 5 years. |
Who may qualify
- Ages
- 18 to 120 years
- Sex
- Female only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| LetrozoleLetrozole 2.5 mg taken orally once daily for 5 years | Drug | Group 2 Letrozole |
| PlaceboPlacebo tablet taken orally once daily for 5 years | Other | Group 1 Placebo |
Primary outcome
Disease-free Survival
Time frame: 7 years.
Percentage of patients free from DFS events. DFS events include local, regional, or distant recurrence, second primary cancer or death from any cause prior to recurrence or second primary cancer.
5 secondary outcomes
Overall Survival
Time frame: 7 years
Breast Cancer-free Interval
Time frame: 7 years
Distant Recurrence
Time frame: 7 years
Osteoporotic-related Fractures
Time frame: 7 years
Arterial Thrombotic Events
Time frame: 7 years
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Mar 2024.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Background: PubMed 17239269Mamounas EP, Lembersky B, Jeong JH, Cronin W, Harkins B, Geyer C, Wickerham DL, Paik S, Costantino J, Wolmark N. NSABP B-42: a clinical trial to determine the efficacy of five years of letrozole compared with placebo in patients completing five years of hormonal therapy consisting of an aromatase inhibitor (AI) or tamoxifen followed by an AI in prolonging disease-free survival in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer. 2006 Dec;7(5):416-21. doi: 10.3816/CBC.2006.n.061. No abstract available.
- Derived from this study: PubMed 39047219Rastogi P, Bandos H, Lucas PC, van 't Veer LJ, Wei JJ, Geyer CE Jr, Fehrenbacher L, Chia SKL, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Paik S, Swain SM, Menicucci AR, Audeh MW, Wolmark N, Mamounas EP. Utility of the 70-Gene MammaPrint Assay for Prediction of Benefit From Extended Letrozole Therapy in the NRG Oncology/NSABP B-42 Trial. J Clin Oncol. 2024 Oct 20;42(30):3561-3569. doi: 10.1200/JCO.23.01995. Epub 2024 Jul 24.
- Derived from this study: PubMed 30509771Mamounas EP, Bandos H, Lembersky BC, Jeong JH, Geyer CE Jr, Rastogi P, Fehrenbacher L, Graham ML, Chia SK, Brufsky AM, Walshe JM, Soori GS, Dakhil SR, Seay TE, Wade JL 3rd, McCarron EC, Paik S, Swain SM, Wickerham DL, Wolmark N. Use of letrozole after aromatase inhibitor-based therapy in postmenopausal breast cancer (NRG Oncology/NSABP B-42): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2019 Jan;20(1):88-99. doi: 10.1016/S1470-2045(18)30621-1. Epub 2018 Nov 30.
- Data Available: Select individual patient-level data from this trial can be requested from the NCTN/NCORP Data ArchiveLink provided by the sponsor.
Related trials for Breast Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Norman Wolmark, MD principal investigator
NSABP Foundation Inc
806 sites in 3 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Letrozole in people with Breast Cancer, run by NSABP Foundation Inc at 806 sites in 3 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 22 Mar 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 806 sites in United States, Canada, Ireland. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 20 May 2021). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Disease-free Survival (time frame: 7 years.). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT00382070, which also lists 3 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Mar 2024.